Humana (NYSE:HUM) Price Target Cut to $370.00

Humana (NYSE:HUM) had its target price cut by research analysts at Oppenheimer from $415.00 to $370.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the insurance provider’s stock. Oppenheimer’s price target would suggest a potential upside of 20.95% from the stock’s current price.

Several other equities research analysts also recently commented on the stock. Stephens reduced their target price on shares of Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a research note on Friday, January 26th. Wells Fargo & Company decreased their price objective on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research report on Monday, April 8th. TD Cowen reduced their price target on Humana from $427.00 to $396.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. The Goldman Sachs Group dropped their price objective on Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. Finally, Truist Financial reiterated a “hold” rating and set a $550.00 price objective on shares of Humana in a research note on Friday, January 19th. Eleven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Humana currently has a consensus rating of “Hold” and a consensus target price of $433.74.

Humana Stock Down 1.8 %

Shares of NYSE:HUM opened at $305.91 on Thursday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.59 and a current ratio of 1.67. Humana has a 1-year low of $299.23 and a 1-year high of $541.21. The company’s fifty day moving average is $327.77 and its two-hundred day moving average is $394.49. The stock has a market capitalization of $36.91 billion, a price-to-earnings ratio of 19.05, a price-to-earnings-growth ratio of 1.85 and a beta of 0.45.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company had revenue of $29.61 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same quarter last year, the firm posted $9.38 EPS. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. Equities analysts anticipate that Humana will post 16.06 EPS for the current year.

Insiders Place Their Bets

In related news, Director Jorge S. Mesquita bought 545 shares of Humana stock in a transaction dated Tuesday, February 20th. The shares were bought at an average cost of $367.09 per share, with a total value of $200,064.05. Following the acquisition, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.32% of the company’s stock.

Institutional Trading of Humana

Large investors have recently modified their holdings of the stock. Rakuten Securities Inc. acquired a new stake in shares of Humana during the 4th quarter worth $25,000. Gradient Investments LLC grew its holdings in shares of Humana by 200.0% during the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 40 shares in the last quarter. Cetera Trust Company N.A acquired a new stake in Humana in the fourth quarter valued at about $28,000. Private Wealth Management Group LLC acquired a new stake in Humana in the fourth quarter valued at about $32,000. Finally, Nvwm LLC boosted its stake in Humana by 41.0% in the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock valued at $42,000 after buying an additional 25 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.